Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23406696 | 1.00 | EGFR (0.70) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL21835274 | 0.91 | EGFR (0.73) | EGFRERBB2KCNH2LCKAURKA | |
| SCHEMBL21835338 | 0.90 | EGFR (0.67) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL21835564 | 0.90 | EGFR (0.67) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL23406641 | 0.89 | EGFR (0.72) | EGFRERBB2KCNH2 | |
| SCHEMBL29087928 | 0.89 | EGFR (0.76) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL30638115 | 0.89 | EGFR (0.76) | EGFRERBB2KCNH2LCKEPHA2 | |
| SCHEMBL21835300 | 0.87 | EGFR (0.56) | EGFRERBB2LCKEPHA2EPHB4 | |
| SCHEMBL5478678 | 0.87 | ERBB2 (0.74) | EGFRERBB2KCNH2 | |
| SCHEMBL21835375 | 0.86 | EGFR (0.74) | EGFRERBB2KCNH2LCKEPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856726-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | Black Diamond Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020068867-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |